MedPath

Biomarkers for Feeding Intolerance in Infants With Complex Congenital Heart Defects Undergoing Single Ventricle Staged Palliation

Conditions
Single Ventricle Physiology
Registration Number
NCT02995577
Lead Sponsor
The University of Texas Health Science Center, Houston
Brief Summary

The purpose of this study is to investigates serum and stool biomarkers as predictors for post-operative feeding intolerance in infant patients with complex congenital heart defects who undergo single ventricle staged palliation surgery.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Full term gestational period (37 weeks gestation or greater)
  • minimum of 2.5kg or greater body weight
  • diagnosis of single ventricle physiology, or complex congenital cyanotic heart disease requiring staged palliation surgery in the form of Norwood-type procedure, systemic-to-pulmonary artery shunt, or pulmonary artery banding.
Exclusion Criteria
  • Have diseases affecting other organs,
  • have major congenital anomalies such as Hirschsprung disease, imperforate anus, CHARGE syndrome, or VACTERL association.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Level of second most abundant serum protein as determined by ELISAbaseline (3-5 days after initial cardiac surgery), within three weeks of the initial cardiac surgery
Level of stool biomarker interleukin-8 (IL-8) as determined by ELISAbaseline (3-5 days after initial cardiac surgery), within three weeks of the initial cardiac surgery
Level of most abundant serum protein as determined by ELISAbaseline (3-5 days after initial cardiac surgery), within three weeks of the initial cardiac surgery

We will select two proteins with top changes that are involved in the pathways for intestinal inflammation, and levels will be determined with either ELISA or other techniques that are available.

Level of stool biomarker calprotectin as determined by ELISAbaseline (3-5 days after initial cardiac surgery), within three weeks of the initial cardiac surgery
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

The University of Texas Health Science Center at Houston

πŸ‡ΊπŸ‡Έ

Houston, Texas, United States

The University of Texas Health Science Center at Houston
πŸ‡ΊπŸ‡ΈHouston, Texas, United States
Supriya Nair, MD
Contact
832-582-0683
Supriya.Nair@uth.tmc.edu

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.